Article Text

Download PDFPDF
Tobacco industry strategies for flavour capsule cigarettes: analysis of patents and internal industry documents
  1. Yvette van der Eijk1,
  2. Ken Wah Teo2,
  3. Grace Ping Ping Tan1,
  4. Wee Meng Chua3
  1. 1 Saw Swee Hock School of Public Health, National University of Singapore, Singapore
  2. 2 Preventive Medicine, National University Health System, Singapore
  3. 3 Department of Biological Sciences, National University of Singapore, Singapore
  1. Correspondence to Dr Yvette van der Eijk, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore 117549; yvette.eijk{at}nus.edu.sg

Abstract

Background The global market for flavour capsule variants (FCVs), cigarettes with a crushable flavour capsule, has grown exponentially. To inform further regulatory efforts, it is important to understand tobacco industry strategies for FCVs.

Methods Analysis of data from 65 patents and 179 internal tobacco industry documents, retrieved via snowball searches in Patsnap and the Truth Tobacco Industry Documents Library, describing tobacco industry developments related to FCVs. We used an inductive coding method to identify themes relating to FCV features or developments.

Results Tobacco companies were developing FCVs since the 1960s, with little market success until the 2000s following the launch of Camel Crush, a brand which targeted millennials (in their teens or early 20s at the time). Tobacco companies have patented, but not yet marketed, FCVs with microcapsule surface coatings, adjustable or heat-triggered flavour release systems, airflow manipulation features, transparent filters to visualise flavour release, and various flavours and additives for capsules including nicotine/tobacco extracts for an on-demand nicotine hit. Tobacco companies developed FCVs purported to be reduced harm, although their own tests showed that FCVs have higher toxicant concentrations. They have also developed loose flavour capsule units designed to fit into cigarettes, packs, or recessed filters to enable users to customise cigarettes and circumvent tobacco flavour bans.

Conclusions To prevent tobacco companies from targeting young people and exploiting regulatory loopholes, regulations on tobacco products should ban flavours and consider the broad variety of FCV designs, additives and loose products designed to impart flavour into tobacco products.

  • advertising and promotion
  • prevention
  • tobacco industry
  • surveillance and monitoring
  • tobacco industry documents

Data availability statement

Data are available in a public, open access repository. The tobacco industry documents are publicly available at https://www.industrydocuments.ucsf.edu/tobacco/. Patents are publicly available online, for example, in databases such as Patsnap or Google Patents.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available in a public, open access repository. The tobacco industry documents are publicly available at https://www.industrydocuments.ucsf.edu/tobacco/. Patents are publicly available online, for example, in databases such as Patsnap or Google Patents.

View Full Text

Footnotes

  • Contributors YvdE—study conceptualisation, study design, data analysis and writing. GPPT and KWT—data collection, data analysis and writing. WMC—data collection and data analysis. All authors reviewed and approved the final draft before submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.